A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in t...
Main Authors: | Patrick A Ott, Anne Hamilton, Amanda Jones, Naomi Haas, Tsiporah Shore, Sandra Liddell, Paul J Christos, L Austin Doyle, Michael Millward, Franco M Muggia, Anna C Pavlick |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2808339?pdf=render |
Similar Items
-
Management of advanced breast cancer with the epothilone B analog, ixabepilone
by: William Gradishar
Published: (2009-06-01) -
Synthesis of epothilones and epothilone analogues
by: Sundermann, Kurt F.
Published: (2012) -
Synthesis, Microtubule-Binding Affinity, and Antiproliferative Activity of New Epothilone Analogs and of an EGFR-Targeted Epothilone-Peptide Conjugate
by: Fabienne Zdenka Gaugaz, et al.
Published: (2019-03-01) -
Profile and potential of ixabepilone in the treatment of pancreatic cancer
by: Smaglo BG, et al.
Published: (2014-07-01) -
Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
by: Hong Shen, et al.
Published: (2016-09-01)